A CAR-T design hits both a tumor and the shield protecting it

Claim

A Nature study found GPNMB sits on both glioblastoma cells and the myeloid shield protecting them, and anti-GPNMB CAR-T cells achieved durable, often curative control in mice by hitting both compartments at once, reframing the tumor as a connected tumor-immune ecosystem.

Reported metric: ~5% five-year survival today

Reporting date: 2026-07-03 (not necessarily the event date)

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

• Welcome to July 3, 2026 (theinnermostloop.substack.com)